Skip to main content

An update on an incident involving one of our systems

Hide
Quest Diagnostics

Prevalence of Opioid Use Among Gabapentin-Positive Urine Specimens

SOFT 2023

Society of Forensic toxicologists

Denver, CO, Oct 29-Nov 3, 2023

Oral presentation: Prevalence of opioid use among gabapentin-positive urine specimens

Authors: Chen L, Jenkins AJ

Specialty: Prescription Drug Monitorig, Toxicology

Related content

Audio Podcast
Contributing Factors to the Skyrocketing Drug Misuse Epidemic in the US
Publication
Notes From the Field: Testing for Nonprescribed Fentanyl and Percentage of Positive Test Results Among Patients with Opioid Use Disorder — United States, 2019–2020
Publication
Shorter Drug Testing Intervals Are Associated With Improved Drug Misuse Rates
Audio Podcast
Why and When to Use Oral Fluid Testing
Audio Podcast
Phosphatidylethanol (PEth) blood test - Now available from Quest Diagnostics
Test FAQ
Drug Monitoring Antidepressants With Confirmation Urine and Serum
Test FAQ
Drug Monitoring, Assess Panel, Comprehensive, Qualitative, Urine

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only. May include AI-generated and/or AI-modified imagery.